SCHEMBL6426529

SCHEMBL6426529

O=C(O)CON=C1C(=O)Nc2c1ccc(Cl)c2Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 4/20 0.49
SIRT2 Q8IXJ6 3/20 0.39
MAPK8 P45983 1/20 0.39
MAPK9 P45984 1/20 0.39
MAPK10 P53779 1/20 0.39
SIRT1 Q96EB6 2/20 0.38
SIRT3 Q9NTG7 1/20 0.38
MAPT P10636 1/20 0.36
PKM P14618 1/20 0.36
PDE1A P54750 1/20 0.33
PDE1B Q01064 1/20 0.33
PDE4D Q08499 1/20 0.33
PDE7A Q13946 1/20 0.33
PDE1C Q14123 1/20 0.33
KMT2A Q03164 1/20 0.33
MCL1 Q07820 1/20 0.32
GALR3 O60755 1/20 0.32
AGTR1 P30556 1/20 0.31
ALPL P05186 1/20 0.31
GPR35 Q9HC97 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6555757 0.79 CES1 (0.56) CES1SIRT2SIRT1SIRT3MAPT
SCHEMBL29386647 0.76 CES1 (0.61) CES1SIRT2SIRT1SIRT3MAPT
SCHEMBL19481154 0.76 CES1 (0.61) CES1SIRT2SIRT1SIRT3MAPT
SCHEMBL30876329 0.76 CES1 (0.61) CES1SIRT2SIRT1SIRT3MAPT
SCHEMBL16279415 0.76 CES1 (0.61) CES1SIRT2SIRT1SIRT3MAPT
SCHEMBL2228834 0.76 CES1 (0.61) CES1SIRT2SIRT1SIRT3MAPT
SCHEMBL6316266 0.75 CES1 (0.51) CES1SIRT2SIRT1SIRT3MAPT
SCHEMBL6317052 0.74 CES1 (0.42) CES1SIRT2SIRT1SIRT3MAPT
SCHEMBL7809424 0.73 MAPK8 (0.39) MAPK8MAPK9MAPK10
Hydrochloric Acid SCHEMBL7826085 0.72 MAPK8 (0.39) MAPK8MAPK9MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1135123-B1 USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS NEUROSEARCH AS (DK) 2004-12-29 EP claimed
WO-2004039409-A2 COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF SWITCH BIOTECH AG (DE) 2004-05-13 WO claimed
EP-1345618-B1 CHLORZOXAZONE FOR THE TREATMENT OF PSORIASIS SWITCH BIOTECH AG (DE) 2005-03-23 EP disclosed
WO-2004039409-A2 COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF SWITCH BIOTECH AG (DE) 2004-05-13 WO disclosed
EP-1345618-A2 USE OF INTERMEDIATE-CONDUCTANCE POTASSIUM CHANNELS AND MODULATORS FOR THE DIAGNOSIS AND TREATMENT OF ILLNESSES HAVING DISTURBED KERATINOCYTE ACTIVITY Switch Biotech Aktiengesellschaft (DE) 2003-09-24 EP disclosed
WO-2002053171-A2 USE OF INTERMEDIATE-CONDUCTANCE POTASSIUM CHANNELS AND MODULATORS FOR THE DIAGNOSIS AND TREATMENT OF ILLNESSES HAVING DISTURBED KERATINOCYTE ACTIVITY SWITCH BIOTECH AKTIENGESELLSCHAFT (DE) 2002-07-11 WO disclosed